UNSPSC 51413202: Cinepazide

This classification denotes a vasodilating agent with the molecular formula C22H31N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67Y4P5C84X, chemically known as 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine but generally known as cinepazide, which bears US NIH Compound Identifier 2759. European Medicines Agency schedules Cinepazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06293MIG.

UNSPSC 51413202 Cinepazide, a Commodity code, represents emergency medications and pharmaceutical supplies that state and local governments procure for emergency medical services, public health agencies, and institutional healthcare programs. State and local buyers under this code source individual drug products — primarily injectable medications used in advanced life support protocols — through direct vendor contracts with fire departments, EMS agencies, health departments, and cooperative purchasing alliances serving multiple jurisdictions. The code encompasses sealed-bid procurements for specific medication line items with defined unit counts, expiration-date requirements, and delivery timelines, as well as broader multi-state cooperative RFPs establishing framework agreements for generic pharmaceuticals and OTC products distributed through authorized wholesalers to participating state agencies and local government facilities.

Recent activity shows issuing bodies spanning city purchasing departments, state health agencies, and regional cooperative purchasing organizations. The City of Tampa Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials) totaling an estimated contract value of $40,000, with a response date of April 8, 2026, and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, with a response deadline of March 26, 2026, and contract effectiveness of July 1, 2026. Geographic activity includes Florida, Texas, Minnesota, and Oregon through the MMCAP cooperative framework.